The circTeloDIAG: Liquid Biopsy for Glioma Tumor

Recruiting now

Conditions studied: Glioma

In brief

Gliomas represent the most frequent primary brain tumor, with 2,500 to 3,000 new cases per year in France. Their diagnosis, although highly complex, is essential for determining patient management. While grade I gliomas (infrequent) are curable by surgery or present a slow progression, grades II to IV require heavy treatment (surgery and radio-chemotherapy), and are associated with a prognosis ranging from 10-15 years for grade II to only 15 months for glioblastoma. One of the key processes in glioma oncogenesis is the activation of a telomeric maintenance mechanism (TMM). Two TMMs ensure the maintenance of a telomere size compatible with intense cell proliferation (TERT mutation and ATRX loss). Liquid biopsy is used for the routine diagnosis and monitoring of treatment efficacy of different cancers. To date, no routine clinical testing of liquid biopsies is available for gliomas. The detection of glioma-specific oncogenic processes, by liquid biopsy, in peripheral blood (ctDNA) could improve diagnosis and follow-up and then avoid surgery for patients with suspected lesions. Three oncogenic markers can be used to detect gliomas: IDH mutation, TERT mutation, and a marker correlated with ATRX loss on total blood cells. We hypothesized that the circTeloDIAG will improve and accelerate the diagnostic/prognostic value of the actual classification and provide a new tool to manage patient response to treatment via liquid biopsy. It will combine detection of three markers in liquid biopsy, to produce a versatile tool for all types of gliomas. Patients with suspected newly diagnosed or recurrent glioma will be included.

Key facts

Study ID

NCT04931732

Run by

Hospices Civils de Lyon

People needed

150

Starts

2021-11-04

Expected to finish

2026-11-01

Last updated by the study team

2023-10-11

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patient
• Obtainment of written informed consent
• Suspected newly or recurrent glioma (grade ≥ II) on MRI
• Patient eligible for surgery (biopsy or resection)
• Decision of surgery (biopsy or resection) at neuro-oncology interdisciplinary tumor board

You may not qualify if…

• Rejection of consent by patient
• Hemoglobin < 7g/dl
• Rejection of surgery by patient
• Suspected grade I tumor on MRI

Where it is running

• East Group Hospital, Hospices Civils de Lyon — Bron, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.